8-K ·Filed May 22, 2026
8-K context-dependent: Items 7.01
Actionable Insight • Neutral
Monitor ASCO presentation for detailed data; no immediate trading catalyst. The safety data reinforces Annamycin's profile but does not change near-term fundamentals.
Final — all horizons settled through T+60d
MBRX ▼ -76.65% at T+60d
NEUTRAL call -76.65% · α vs SPY -79.38% · entry $2.45 → $0.5720
T+1d
+9.18%
call +9.18% · α +9.23%
$2.68
settled 5mo ago
T+5d
+7.76%
call +7.76% · α +6.67%
$2.64
settled 5mo ago
T+20d
+18.32%
call +18.32% · α +20.27%
$2.90
settled 4mo ago
T+60d
-76.65%
call -76.65% · α -79.38%
$0.5720
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Moleculin announced that an abstract on pooled cardiac safety data for Annamycin has been accepted for a poster presentation at the 2026 ASCO Annual Meeting. The data show no cardiotoxicity signals in 90 patients, supporting the drug's safety profile. This is a routine clinical update with no new efficacy or financial data.
Key Facts
- Abstract accepted for poster presentation at ASCO 2026 (May 29–June 2, 2026).
- Pooled cardiac safety data from 90 patients across 5 trials: no statistically significant LVEF change (mean difference -0.12%, p=0.84).
- Median cumulative Annamycin dose 660 mg/m² (range 210–2,970 mg/m²), exceeding conventional anthracycline limits.
- No evidence of drug-induced cardiotoxicity by ECG, biomarkers, or adverse events.
- Previously reported Phase 1b/2 data: 50% CR, 60% CRc, median OS 12.39 months.
Financial Impact
No financial impact disclosed.
Risk Factors
- Clinical trial risks for ongoing Phase 2b/3 MIRACLE trial.
- Need for additional financing as noted in forward-looking statements.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018242 |
| Exhibit: ex_967284.htm | 0001437749-26-018242 |
| Document: 0001437749-26-018242-index-headers.html | 0001437749-26-018242 |
| Document: 0001437749-26-018242-index.html | 0001437749-26-018242 |
| Document: 0001437749-26-018242.txt | 0001437749-26-018242 |
30 reports for MBRX
50% Hit rate @ T+20 Went positive at some point 10 of 16 best @ T+60▲ +1671.25%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
Showing 10 of 30
US Market Status
Market Closed — Opens in 6h 51m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers